Form 4: Adaptive Biotechnologies SVP Stacy L. Taylor Sells Shares Under 10b5-1 Plan

Stacy L. Taylor, SVP and General Counsel of Adaptive Biotechnologies, sold 26,922 shares of common stock at a weighted-average price of $4.4974 on August 22, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On August 22, 2024, Stacy L. Taylor, the SVP and General Counsel of Adaptive Biotechnologies, sold 26,922 shares of common stock.
• The sale was executed at a weighted-average price of $4.4974 per share.
• The transactions occurred within a price range of $4.415 to $4.62.
• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on May 23, 2024.
• Following the transaction, Taylor directly owns 139,365 shares of Adaptive Biotechnologies Corp.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock sale under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales by company insiders are a normal part of corporate governance. The fact that the sale was executed under a 10b5-1 plan suggests it was pre-planned and not based on any immediate inside information.

Stakeholder Impact

• The sale of shares by an executive could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates this concern.

Key Dates